Contineum Therapeutics, Inc. · NASDAQ:CTNM
Balyasny Asset Management L.P. reported a 7.40% stake in Contineum Therapeutics, Inc. (Schedule 13G)
Event Mar 31, 2026 · Filed May 15, 2026
Balyasny Asset Management L.P. reported a 7.40% stake in Contineum Therapeutics, Inc., 2,417,723 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G).
- Stake
- 7.40%
- Shares
- 2,417,723
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Balyasny Asset Management L.P. | 7.40% | 2,417,723 |
| BAM GP LLC | 7.40% | 2,417,723 |
| Balyasny Asset Management Holdings LP | 7.40% | 2,417,723 |
| Dames GP LLC | 7.40% | 2,417,723 |
| Dmitry Balyasny | 7.40% | 2,417,723 |
Source
Related
- Contineum Therapeutics, Inc.
- Balyasny Asset Management L.P.
- Contineum Therapeutics, Inc. shareholders
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Schedule 13G · Balyasny Asset Management L.P. · Feb 17, 2026
- Schedule 13G · Trails Edge Capital Partners, LP · Oct 22, 2026
- Form 4 · Stengone Carmine N. · Sep 8, 2026
- Form 4 · Stengone Carmine N. · Aug 3, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · Millennium Management LLC · Jul 17, 2026